Raymond James initiated coverage on ARS Pharmaceuticals with a new price target

7/25/24 6:43:09 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Raymond James initiated coverage of ARS Pharmaceuticals with a rating of Outperform and set a new price target of $18.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SPRY

Date	Price Target	Rating	Analyst
3/7/2025	$30.00	Sector Outperform	Scotiabank
2/10/2025	$40.00	Outperform	Oppenheimer
8/20/2024		Overweight	Cantor Fitzgerald
8/13/2024	$18.00 → $22.00	Outperform → Strong Buy	Raymond James
8/12/2024	$19.00 → $20.00	Outperform	Leerink Partners
7/25/2024	$18.00	Outperform	Raymond James
3/5/2024	$6.00 → $18.00	Market Perform → Outperform	Leerink Partners
2/20/2024		Mkt Perform → Outperform	William Blair